Genomic and phenotypic profiles of two Brazilian breast cancer cell lines derived from primary human tumors

Oncology Reports

Volumn 29, Issue 4, 2013, Pages 1299-1307

  Correa, Natássia C R ^a   Kuasne, Hellen ^b   Faria, Jerusa A Q A ^a   Seixas, Cica C S ^a   Santos, Iria G D ^a   Abreu, Francine B ^c   Nonogaki, Suely ^d   Rocha, Rafael M ^d   Silva, Gerluza Aparecida Borges ^c   Gobbi, Helenice ^a   Rogatto, Silvia R ^c,e   Goes, Alfredo M ^a   Gomes, Dawidson A ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b STATE UNIVERSITY OF LONDRINA   (Brazil)

^c Laboratory of Investigative and Molecular Pathology CIPED   (Brazil)

^d A C CAMARGO CANCER CENTER   (Brazil)

^e SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Array comparative genomic hybridization; Breast cancer; Cell line; Immunohistochemistry; Primary tumor; Tumor xenograft

Indexed keywords

AGAR; CELL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENOMIC DNA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HORMONE RECEPTOR; MUCIN 1; TELOMERASE;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; COMPARATIVE STUDY; CONTROLLED STUDY; COPY NUMBER VARIATION; GENOMICS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MACL 1 CELL; MGSO 3 CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; STEM CELL; TUMOR CELLS AND CELL LINES; TUMOR XENOGRAFT;

ANIMALS; BRAZIL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; HUMANS; MICE; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874722716     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2284     Document Type: Article

References (40)

1. INCA: Estimativa 2012: Incidência de câncer no Brasil. Instituto Nacional de Câncer José Alencar Gomes da Silva, Coordenação Geral de Ações Estratégicas, Coordenação de Prevenção e Vigilância. Rio de Janeiro, p188, 2011.
2. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134: e48-e72, 2010.
3. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131: 18-43, 2007.
4. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B and Senn HJ: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer. Ann Oncol 20: 1319-1329, 2009.
5. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
6. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.
7. Sorlie T, Perou CM, Fan C, Geisler S, Aas T, Nobel A, et al: Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther 5: 2914-2918, 2006.
8. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al: Repeated observation of breast tumor subtypes in indepen¬dent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423, 2003.
9. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al: Phenotypic and molecular characterization of the claudin low intrinsic subtype of breast cancer. Breast Cancer Res 12: R68, 2010.
10. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, et al: Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 4: e6146, 2009.
11. Correa CR, Bertollo CM and Goes AM: Establishment and char¬acterization of MACL-1 and MGSO-3 cell lines derived from human primary breast cancer. Oncol Res 17: 473-482, 2009.
12. Correa CR, Bertollo CM, Zouain CS and Goes AM: Glyceraldehyde-3-phosphate dehydrogenase as a surface asso¬ciated antigen on human breast cancer cell lines MACL-1 and MGSO-3. Oncol Rep 24: 677-685, 2010.
13. Bertollo CM, Correa CR, Gomes DA, Souza-Fagundes EM and Goes AM: Effect of radiation treatment on newly established human breast cancer cell lines MACL-1 and MGSO-3. Tumour Biol 31: 189-197, 2010.
14. Yerushalmi R, Woods R, Ravdin PM, Hayes MM and Gelmon KA: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11: 174-183, 2010.
15. Al Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003.
16. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV and Varticovski L: Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10: R10, 2008.
17. Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc 1: 2315-2319, 2006.
18. Sambrook J and Russel DW: Isolation of High-molecular-weight DNA from mammalian cells using proteinase K and phenol. In: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001.
19. Lim SC: CD24 and human carcinoma: tumor biological aspects. Biomed Pharmacother 59 (Suppl 2): S351-S354, 2005.
20. Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, et al: CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 65: 10783-10793, 2005.
21. Kristiansen G, Sammar M and Altevogt P: Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 35: 255-262, 2004.
22. O'Hare MJ: Breast cancer. In: Human Cancer in Primary Culture, A Handbook. Masters JRW (ed). Kluwer Academic Publishers, London, pp271-286, 1991.
23. Kim JB, O'Hare MJ and Stein R: Models of breast cancer: is merging human and animal models the future? Breast Cancer Res 6: 22-30, 2004.
24. Brozova M, Kleibl Z, Netikova I, Sevcik J, Scholzova E, Brezinova J, et al: Establishment, growth and in vivo differ¬entiation of a new clonal human cell line, EM-G3, derived from breast cancer progenitors. Breast Cancer Res Treat 103: 247-257, 2007.
25. Strojnik T, Kavalar R, Barone TA and Plunkett RJ: Experimental model and immunohistochemical comparison of U87 human glioblastoma cell xenografts on the chicken chorioallantoic membrane and in rat brains. Anticancer Res 30: 4851-4860, 2010.
26. Tsuji K, Kawauchi S, Saito S, Furuya T, Ikemoto K, Nakao M, et al: Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues. BMC Cancer 10: 15, 2010.
27. Smiraglia DJ, Rush LJ, Fruhwald MC, Dai Z, Held WA, Costello JF, et al: Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet 10: 1413-1419, 2001.
28. Vargo-Gogola T and Rosen JM: Modelling breast cancer: one size does not fit all. Nat Rev Cancer 7: 659-672, 2007.
29. Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, Yu J, et al: Integrative analysis of genomic aberrations associ¬ated with prostate cancer progression. Cancer Res 67: 8229-8239, 2007.
30. Clark J, Edwards S, Feber A, Flohr P, John M, Giddings I, et al: Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene 22: 1247-1252, 2003.
31. Mora J, Cheung NK, Chen L, Qin J and Gerald W: Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clin Cancer Res 7: 1358-1361, 2001.
32. Barbashina V, Salazar P, Holland EC, Rosenblum MK and Ladanyi M: Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 11: 1119-1128, 2005.
33. Chou D, Miyashita T, Mohrenweiser HW, Ueki K, Kastury K, Druck T, et al: The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. Cancer Genet Cytogenet 88: 136-140, 1996.
34. Smith JS, Tachibana I, Pohl U, Lee HK, Thanarajasingam U, Portier BP, et al: A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics 64: 44-50, 2000.
35. Iida A, Kurose K, Isobe R, Akiyama F, Sakamoto G, Yoshimoto M, et al: Mapping of a new target region of allelic loss to a 2-cM interval at 22q13.1 in primary breast cancer. Genes Chromosomes Cancer 21: 108-112, 1998.
36. Bieche I and Lidereau R: Genetic alterations in breast cancer. Genes Chromosomes Cancer 14: 227-251, 1995.
37. Sato T, Tanigami A, Yamakawa K, Akiyama F, Kasumi F, Sakamoto G and Nakamura Y: Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res 50: 7184-7189, 1990.
38. Allione F, Eisinger F, Parc P, Noguchi T, Sobol H and Birnbaum D: Loss of heterozygosity at loci from chromosome arm 22Q in human sporadic breast carcinomas. Int J Cancer 75: 181-186, 1998.
39. Benetkiewicz M, Piotrowski A, Díaz De Ståhl T, Jankowski M, Bala D, Hoffman J, et al: Chromosome 22 array-CGH profiling of breast cancer delimited minimal common regions of genomic imbalances and revealed frequent intra-tumoral genetic hetero¬geneity. Int J Oncol 29: 935-945, 2006.
40. Hollmann TJ and Hornick JL: INI1-deficient tumors: diagnostic features and molecular genetics. Am J Surg Pathol 35: e47-e63, 2011.